Latest News On Drug Costs

Latest California Healthline Stories

Top California Democrats Clash Over How To Rein In Drug Industry Middlemen

Frustrated by spiraling drug costs, California lawmakers want to increase oversight of pharmaceutical industry intermediaries known as pharmacy benefit managers. It’s unclear whether they can persuade Gov. Gavin Newsom to get on board.

What To Know About Trump’s Executive Orders on US Health Care 

From rolling back drug pricing policies to limiting gender-affirming care, President Donald Trump signed several health-related executive orders in the first hours of his second presidency. Here’s a roundup of the changes and what they mean.

KFF Health News' 'What the Health?': Hello, Trump. Bye-Bye, Biden.

With just days to go before the official launch of a new administration, the GOP-led Congress is putting together plans on how to enact incoming President Donald Trump’s agenda, with a particular emphasis on cutting spending on the Medicaid program. Meanwhile, the Biden administration makes major moves in its last days, including banning a controversial food dye and ordering cigarette companies to minimize their nicotine content. Joanne Kenen of Johns Hopkins University and Politico Magazine, Anna Edney of Bloomberg News, and Sandhya Raman of CQ Roll Call join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews Harris Meyer, who reported and wrote the latest KFF Health News “Bill of the Month” feature, about a colonoscopy that came with a much larger price tag than estimated.

Health Care Is Newsom’s Biggest Unfinished Project. Trump Complicates That Task.

As Gov. Gavin Newsom enters the second half of his final term, health care stands out as his most ambitious but glaringly incomplete initiative for California residents. The issue will likely shape his national profile for better or worse. And now, Donald Trump brings a new wrinkle.

Florida Gov. DeSantis’ Canadian Drug Import Plan Goes Nowhere After FDA Approval

Florida sued the FDA over what it said was a “reckless delay” in approving its drug importation plan. Now, nearly a year after the FDA gave the state the green light, the program has yet to begin.